Background {#S1}
==========

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal pathogen responsible for coronavirus disease 2019 (COVID-19), enters human cells by engaging angiotensin-converting enzyme 2 (ACE2)^[@R1]^. This interaction may lead to an imbalance of the renin-angiotensin-aldosterone system (RAAS), a potential mechanism contributing to this pathogen's virulence^[@R2]^. A combination of direct viral toxicity and indirect effects such as untempered thromboinflammation and dysregulation of the RAAS may underlie severe presentations of COVID-19, which can manifest with acute respiratory distress syndrome (ARDS), myocardial injury, and micro-and macro-thrombotic events^[@R3]^. As such, several anti-inflammatory, immunomodulatory, and antithrombotic therapies may hold promise for prevention or treatment of patients with COVID-19^[@R4]^, and statins constitute one such class of medications.

Although statins have traditionally been administered to lower serum cholesterol, their pleiotropic effects, including anti-inflammatory and antithrombotic properties, make them an attractive class of drugs in the setting of COVID-19^[@R5]-[@R8]^. Moreover, through effects on lipid rafts in cellular membranes^[@R9]-[@R12]^, statins may influence viral transmission and infectivity. By these putative mechanisms, statins appear to have the potential to mitigate the impact of myocardial injury and thrombotic events that are associated with severe COVID-19 presentations^[@R13]^.

To date, a number of studies have evaluated the use of statins in the treatment of pneumonia and ARDS^[@R5],[@R14]-[@R20]^. While primary results of randomized clinical trials evaluating statins in ARDS have not indicated a benefit^[@R19],[@R20]^, secondary analysis of 540 individuals from the HARP-2 (Hydroxymethylglutaryl-CoA Reductase Inhibition with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction--2) trial demonstrated improved survival with statin treatment in patients with a hyperinflammatory phenotype^[@R15]^.

Therefore, we hypothesized that antecedent outpatient statin use may be associated with better clinical outcomes in patients hospitalized with COVID-19. In the current study, we sought to compare patient baseline and presentation characteristics as well as clinical outcomes, including in-hospital mortality, stratified by antecedent statin use, in a cohort of patients admitted with COVID-19 to a quaternary academic medical center in New York City.

Methods {#S2}
=======

Patient population and data elements. {#S3}
-------------------------------------

For this retrospective study, we utilized data from the Columbia University Irving Medical Center (CUIMC) and Allen Hospital sites of the NewYork-Presbyterian Hospital (NYPH). Adult patients (≥18 years of age) who were hospitalized between February 1^st^ through May 12^th^, 2020, and tested positive for SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) testing of nasopharyngeal or oropharyngeal specimens were included in the present analysis. All testing was conducted either by NYPH laboratories or the New York State Department of Health (in the period of time prior to when internal testing capabilities were available). Patients who were admitted for less than 24 hours were excluded from this analysis. The study period ended on June 11^th^, 2020, allowing for a follow-up period of at least 30 days in all patients. The CUIMC Institutional Review Board approved this study and waived the requirement for obtaining informed consent. De-identified data will be made available on request to the corresponding authors.

Patient data were identified in the electronic medical record by using the institution's clinical data warehouse, which includes outpatient and inpatient information on individuals who receive care at our institution. No manual chart abstraction was performed. Follow-up for each patient continued until patients were discharged, died in-hospital, or the end of the study period was reached. Data analysis was limited to the index hospitalization in the event of readmissions. Baseline information including age, gender, race and ethnicity, insurance, New York City borough of residence, body mass index (BMI), comorbidities, and outpatient medications were recorded. Clinical comorbidities, including hypertension, diabetes, coronary artery disease, heart failure, stroke or transient ischemic attack, atrial arrhythmias (atrial fibrillation, atrial flutter and supraventricular tachycardia), chronic lung disease, chronic kidney disease, and chronic liver disease were identified using ICD-10 medical billing codes ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). Outpatient medications, including statins, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers, oral anticoagulants, and P2Y12 inhibitors were extracted from medication reconciliation fields in the electronic medical record, which are entries that are updated at the time of hospital admission.

We included features of the clinical presentation, including vital signs at presentation (i.e. temperature, heart rate, blood pressure, respiratory rate, and peripheral oxygen saturation). Several laboratory parameters at presentation were also collected from the electronic medical record, including white blood cell count, platelet count, creatinine, hepatic panel tests including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin, lactate, high-sensitivity troponin T, D-dimer, ferritin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Given that statins may act by lowering lipid levels, we collected lipid values for patients from inpatient and outpatient records at any dates after January 1^st^ 2018, and averaged them for each patient over the study period. As some patients did not have all laboratory studies of interest collected as part of clinical care, data are presented for only the patients in whom these were available. Details for missing laboratory values are provided in the [Supplemental Table 2](#SD1){ref-type="supplementary-material"}.

Study exposure. {#S4}
---------------

The exposure in this study was antecedent statin use. Antecedent statin use was defined as record of statins as a home medication in the electronic medical record.

Study outcomes. {#S5}
---------------

The principal outcome was in-hospital mortality within 30 days of admission. The secondary outcome was a composite of in-hospital mortality or invasive mechanical ventilation within 30 days of admission. Other outcomes included in-hospital mortality at any time and invasive mechanical ventilation at any time, as some patients had a length of stay longer than 30 days. We also examined hospital length of stay (days), duration of invasive mechanical ventilation (days), renal replacement therapy with continuous veno-venous hemofiltration, and use of vasopressors.

Statistical analysis. {#S6}
---------------------

We examined differences in socio-demographic, baseline clinical characteristics, and outpatient medications by antecedent statin use. Summary statistics are presented as numbers and percentages for categorical variables and medians and interquartile ranges for continuous variables. Differences between groups were examined using the 2-sided independent t-test and chi-squared test, as appropriate.

To address confounding by indication, we constructed a multivariable logistic regression model to predict the propensity of antecedent statin administration, adjusted for the following variables: age, sex, first BMI assessment, race and ethnicity, insurance, New York City borough of residence, history of hypertension, diabetes, coronary artery disease, heart failure, stroke or transient ischemic attack, atrial arrhythmias, chronic lung disease, chronic kidney disease, and liver disease; outpatient use of beta-blockers, ACEi, ARBs, oral anticoagulants, and P2Y~12~ receptor inhibitors. Propensity-score matching was implemented with the use of a nearest-neighbor strategy with specification of caliper width equal to 0.1 of the standard deviation of the logit of the propensity score. Descriptive analyses were performed for all baseline variables in the propensity-matched cohort.

For the primary and secondary endpoints, we performed logistic regression on the propensity-matched cohort. In addition, to examine whether the effect estimate remained consistent in the overall cohort, we performed logistic regression with multivariable adjustment on the overall cohort. We adjusted the multivariable models for variables that have been previously studied in association with mortality in COVID-19 including baseline socio-demographic and clinical characteristics and outpatient medications.^[@R21],[@R22]^

Sensitivity Analyses. {#S7}
---------------------

We performed sensitivity analyses by defining any recent statin use as either antecedent statin or inpatient statin use. Using this definition, we evaluated the association of any recent statin use with the primary endpoint using multivariable logistic regression. We also performed subgroup analyses to assess the association of antecedent statin use with primary endpoint in a subset of patients with history of hypertension, coronary artery disease and stroke, conditions for which statins are usually prescribed.

Missing data. {#S8}
-------------

BMI and insurance information were missing in 19% and 15% of the patients, respectively, and multiple imputation with predictive mean matching was utilized to adjust the models for BMI and insurance. We imputed one hundred datasets, fitted the logistic regression models for the primary and secondary endpoints for each imputed dataset, estimated the hazard ratios on each imputed dataset, and then averaged the one hundred estimated values to obtain the pooled estimates. Model estimates and standard errors were calculated with Rubin's rules^[@R11]^. Race and ethnicity were missing in 30% of the patients and were classified as 'others/missing' while adjusting in the models. Lipid levels were available for only 32% of the cohort. As such, we have presented them only at baseline. The remaining variables were missing in fewer than 5% of the study cohort.

P-values \<0.05 were considered significant for the analysis. We did not adjust for multiple comparisons as this was an exploratory analysis. All analyses were performed using version 3.5.1 of the R programming language (R Project for Statistical Computing; R Foundation, mice, MatchIt, cobalt, rms packages).

Results {#S9}
=======

Baseline Patient Characteristics. {#S10}
---------------------------------

Of 2626 patients included in the analysis, 951 (36.2%) were considered antecedent statin users ([Table 1](#T1){ref-type="table"}). On average, patients who were prescribed statins were older (\[median 70 (IQR 63-79) vs. 62 (49-76) years, p\<0.001\] with no significant differences in sex (p=0.06) or race/ethnicity (p=0.12). Patients in the statin group were significantly more likely to have Medicare or Medicaid (63.0% vs. 53.6%) insurance, and less likely to be have commercial insurance (35.4% vs. 42.5%) (p \<0.001 for both). There was no significant difference in the New York City borough of residence in the two groups.

Furthermore, patients using statins were significantly more likely to have hypertension (74.0% vs. 43.3%), diabetes (55.8% vs. 26.1%), coronary artery disease (22.5% vs. 6.9%), heart failure (17.0% vs. 6.7%), and chronic kidney disease (22.0% vs. 9.6%) compared with patients not receiving statins (p\<0.001 for all). Similarly, patients receiving statins had higher rates of history of stroke/transient ischemic attack (13.9% vs. 5.6%) and atrial arrhythmias (11.0% vs. 5.6%), p\<0.001 for both. There were no significant differences in liver disease between the two groups.

Patients on statins were significantly more likely to be prescribed angiotensin-converting enzyme inhibitors (19.7% vs. 4.2%), angiotensin-receptor blockers (13.1% vs. 3.7%), P2Y12 inhibitors (11.9% s. 1.1%), oral anticoagulants (20.3% vs. 12.3%), and beta-blockers (44.0% vs. 12.7%) as outpatients compared to those not taking statins (p\<0.001 for all). Of note, 77.0% of patients who were on antecedent statins and 8.6% of patients who were not on antecedent statins, received statins during hospitalization.

Furthermore, among the 850 patients for whom lipid levels were available, patients receiving statins had significantly lower mean low-density lipoprotein \[77.9 (60.0 -- 107.6) vs. 88.0 (67.0 -- 117.0)\] and total cholesterol levels \[157.3 (127.7 -- 191.0) vs. 164.9 (136.0 -- 201.9)\] compared with those who were not receiving them (p\<0.01 for all).

Propensity-Matched Cohort Characteristics. {#S11}
------------------------------------------

Using 1:1 matching, a propensity-matched cohort of 1296 patients (648 patients on statins, 648 patients not on statins) was identified. No significant differences in demographics, comorbidities, or home medications remained in the propensity-matched cohort ([Table 1](#T1){ref-type="table"}). The distribution of the estimated propensity scores for receipt of statins among patients who did and did not receive outpatient statins is shown in [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}. In the matched analytic sample, the differences between pre-hospitalization variables were attenuated in the propensity-score--matched samples as compared with the unmatched samples ([Supplemental Figure 2](#SD1){ref-type="supplementary-material"}).

At the time of initial presentation, patients receiving statins were less likely to present with tachypnea (22.1% vs. 28.7%, p\<0.01). There were no significant differences in presence of fever, tachycardia, peripheral desaturation or hypotension on initial assessment ([Table 2](#T2){ref-type="table"}).

In the propensity-matched cohort, patients on statins had significantly lower white blood cell count at presentation \[7.6 (5.5 -- 10.3) vs. 8.1 (5.8 -- 11.6)\] and lower CRP levels \[100.0 (46.2 -- 168.5) vs. 120.7 (61.2 -- 194.9)\] (p\<0.01 for both) ([Table 2](#T2){ref-type="table"}). There were no significant differences in high-sensitivity troponin T, D-dimer, ferritin, or ESR levels between groups.

Clinical Outcomes of Propensity-Matched Cohort. {#S12}
-----------------------------------------------

Differences in clinical outcomes in the propensity-matched sample are presented in [Table 3](#T3){ref-type="table"}. The primary endpoint occurred in 96 (14.8%) patients receiving statins compared to 172 (26.5%) not receiving statins, (OR 0.48, 95% CI 0.36 -- 0.64, p\<0.001). The secondary endpoint occurred in 179 (27.6%) patients receiving statins compared to 269 (41.5%) not receiving statins, (OR 0.54, 95% CI 0.43 -- 0.68, p\<0.001). Patients with antecedent statin use had lower rates of in-hospital mortality at any time compared with individuals who were not on statins (20.8% vs. 33.7%, OR 0.46, 95% CI 0.36 -- 0.60, p\<0.001). There were no significant differences in invasive mechanical ventilation, vasopressor use, renal replacement therapy, or length of stay between the groups.

Multivariable Adjustment In Overall Cohort. {#S13}
-------------------------------------------

Statin use was significantly associated with a reduction in the primary endpoint (in-hospital mortality within 30 days) in the overall cohort in univariate (OR 0.69, 95% CI 0.56-0.85) and multivariable adjusted analysis (OR 0.49, 95% CI 0.38-0.63) ([Table 4](#T4){ref-type="table"}). Other factors associated with increased odds of the primary endpoint included age, male sex, history of atrial arrhythmias, and diabetes ([Figure 1](#F1){ref-type="fig"}). Outpatient prescriptions of oral anticoagulants and P2Y12 inhibitor were also protective. These results were in agreement with sensitivity analyses performed within the dataset restricted to patients with hypertension, coronary artery disease and stroke/transient ischemic attack, and in the dataset with modified definition of antecedent statin use ([Supplemental Figures 3](#SD1){ref-type="supplementary-material"} and [4](#SD1){ref-type="supplementary-material"}).

In addition, statin use was associated with reduced hazards of the secondary endpoint in the overall cohort in univariate (OR 0.75, 95% CI 0.63-0.89) and multivariable adjusted analysis (OR 0.54, 95% CI 0.44 -- 0.67) ([Table 4](#T4){ref-type="table"}). Other factors associated with increased odds of secondary endpoint included male sex, age, history of atrial arrhythmias, diabetes, and stroke/TIA ([Figure 2](#F2){ref-type="fig"}).

Discussion {#S14}
==========

The principal findings of this detailed analysis regarding antecedent statin use in hospitalized patients with COVID-19 are 1) antecedent statin use was common in our cohort, as 36% of patients admitted to our institution were prescribed statins prior to their index admission; 2) patients receiving statins were older, with a higher burden of cardiovascular comorbidities, 3) patients receiving statins tended to present with lower levels of CRP, and 4) antecedent statin use was associated with significantly lower odds of patients experiencing the primary endpoint of in-hospital mortality within 30 days as well as the secondary endpoint of in-hospital mortality or invasive mechanical ventilation requirement within 30 days in a propensity-matched analysis.

In addition to respiratory failure due to pneumonia and ARDS, COVID-19 is known to result in a number of extrapulmonary manifestations^[@R23]^. Posited mechanisms explaining the multiorgan dysfunction that can result from severe COVID-19 presentations include but are not limited to direct effects of SARS-CoV-2 infection as well as indirect effects of a dysregulated immune response and hyperinflammatory state^[@R23]^. This is supported by clinical and laboratory markers of inflammation, as well as histopathologic and post-mortem data, which demonstrate extensive inflammation and endothelialitis as well as isolation of viral RNA in tissues from several organ systems in patients with COVID-19^[@R23]-[@R27]^. Cardiovascular complications, specifically myocardial injury and thrombotic complications, are common and relate closely to prognosis^[@R13]^. Therefore, identifying treatment strategies to prevent serious sequelae of this viral infection may have the potential to improve prognosis. The current analysis suggests that statins merit further evaluation as prophylactic and treatment agents for patients with COVID-19 given their pleiotropic properties and potentially disease-modifying effects in the setting of this viral illness.

There are many potential explanations as to how statins may have contributed to lower 30-day in-hospital mortality and invasive mechanical ventilation in our cohort, despite high prevalence of cardiovascular comorbidities in patients with antecedent statin use. Statins, which target HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, confer a significant mortality benefit in patients with atherosclerotic cardiovascular disease^[@R5],[@R28],[@R29]^, who are overrepresented in hospitalized patients with COVID-19. In addition to hyperlipidemia and a number of other cardiovascular risk factors, inflammation has been identified as a key modulator of atherogenesis and can contribute considerably to adverse cardiovascular events^[@R5],[@R30],[@R31]^. The potential benefits from statins extend beyond cholesterol-lowering properties, as there is a robust literature supporting the anti-inflammatory properties of statins in the preclinical and clinical arenas, suggesting that these drugs can stabilize and restore endothelial function, and lower rates of circulating inflammatory biomarkers such as CRP^[@R5],[@R32]^. Patients receiving statins presented with significantly lower CRP levels in this cohort compared with those who were not on statins.

Plaque stabilization^[@R33],[@R34]^ and anti-thrombotic properties^[@R35]^ are also favorable characteristics of this class of drugs. It has previously been demonstrated in several series of COVID-19 patients that pre-existing cardiovascular disease is associated with risk for clinical decompensation and severe disease^[@R13],[@R36]^. Therefore, it is conceivable that antecedent statin use may confer benefit by preventing myocardial injury and infarction as well as thrombotic events, both of which may have influenced mortality and endotracheal intubation rates, due to their multitude of effects. Similar mechanism may plausibly explain the association of outpatient use of antiplatelet agents and anticoagulants with lower mortality in patients with COVID-19, although these were not the focus of our study.

Other mechanisms, which may explain the effects of statin use in patients with COVID-19, have also been suggested. Functional membrane microdomains or lipid rafts consist of cholesterol and sphingolipids^[@R9]-[@R11]^, and viruses may gain entry to cells via receptors which are concentrated in these regions of the plasma membrane^[@R12]^. Thus, it has been theorized that statin-mediated reduction in cholesterol levels may sufficiently alter the makeup of these lipid rafts^[@R12]^, potentially preventing or reducing likelihood for viral infection or replication, and hence disease severity. Though lipid levels were not available for our entire cohort, we did find lower levels of total cholesterol and low-density lipoprotein in patients receiving statins. Additionally, a recent computational docking analysis was performed to assess the interaction between an important SARS-CoV-2 protease (Mpro)^[@R37]^ and statins^[@R38]^. Interestingly, these authors found that several statins demonstrated stronger interactions with Mpro than some protease inhibitors, implicating a potential mechanism by which statins may be able to interfere with SARS-CoV-2 replication. Preclinical evidence suggests that statin use (as with ACEi and ARBs) can contribute to increased ACE2 expression and epigenetic modification^[@R39]^. As ACE2 serves as the entry point for SARS-CoV-2 to human hosts, it remains to be completely understood how the modulation and modification of ACE2 levels may impact viral replication and infectivity.

In addition to the mechanisms above, studies prior to the current COVID-19 era evaluated the use of statins to prevent progression of ARDS and limit severity of illness^[@R5],[@R15],[@R19],[@R40],[@R41]^, and evidence in this space is incomplete. While the primary results of the randomized SAILS (Statin for Acutely Injured Lungs From Sepsis) and HARP-2 trials did not demonstrate any benefit to statin use in ARDS^[@R19],[@R20]^, a secondary analysis of HARP-2 suggested improved survival with statin use in a hyperinflammatory phenotype^[@R15]^. Subphenotype analysis of SAILS did not replicate these results^[@R42]^. In light of these dissimilar findings, it is important to note that these trials administered different drugs and were characterized by different inclusion criteria^[@R43]^. Whether specific statins confer greater benefit due to higher bioavailability in lung tissue or more profound pleiotropic effects remains to be completely understood. However, the benefit noted from statins in our cohort may share mechanisms with some of the prior positive statin studies in the ARDS literature.

The limited evidence available regarding statins in the COVID-19 literature confirms the findings presented in the present manuscript. In a separate study which evaluated the prevalence and impact of myocardial injury in 2,736 hospitalized patients to the Mount Sinai Hospital System in New York City, 36% of this cohort was receiving statins prior to admission^[@R44]^. In their multivariable model, while not the focus of their analysis, statin use was associated with significantly lower rates of in-hospital mortality (OR 0.57, 95% CI 0.47-0.69)^[@R44]^. Additionally, a separate study of 154 elderly individuals (mean age 86 years) suggested that statin use prior to admission was associated with less severe symptoms, but they did not assess in-hospital mortality^[@R45]^. Most recently, an analysis from the Wuhan, China demonstrated significantly lower 28-day mortality in patients who received inpatient statins compared with non-statin users (adjusted hazard ratio 0.58 \[0.43-0.80)^[@R46]^. In this study, however, less than 10% of hospitalized patients received statins, and may not be representative of Western populations with higher burden of cardiovascular comorbidities. Moreover, their focus on in-hospital statin use in an observational setting may be subject to immortal time bias. With these studies as well as the findings of the present analysis in mind, the results of ongoing randomized clinical trials and registries will be crucial, as they may provide important prospective data regarding the potential benefits of statin therapy in COVID-19 ([Clinicaltrials.gov](http://Clinicaltrials.gov) Identifiers: [NCT04407273](https://clinicaltrials.gov/ct2/show/NCT04407273), [NCT04390074](https://clinicaltrials.gov/ct2/show/NCT04390074), [NCT04348695](https://clinicaltrials.gov/ct2/show/NCT04348695), [NCT04426084](https://clinicaltrials.gov/ct2/show/NCT04426084), [NCT04333407](https://clinicaltrials.gov/ct2/show/NCT04333407), and [NCT04380402](https://clinicaltrials.gov/ct2/show/NCT04380402)).

Limitations. {#S15}
------------

Our study has important limitations. As a retrospective analysis of electronic medical record data, there remains the potential for unmeasured confounders. However, we performed propensity matched analysis and multivariable adjustment with logistic regression to control for a number of demographic and clinical characteristics to minimize the likelihood for confounding. Additionally, we also performed a number of sensitivity analyses, including assessing outcomes in patients who received either outpatient or inpatient statins, and analyses restricted to cohort with cardiovascular disease, and findings remained consistent. Additionally, medication reporting and reconciliation in the electronic medical record, especially in the setting of the ongoing pandemic, may have been subject to errors on the part of individual clinicians. Moreover, given this mechanism of assessing antecedent statin use, it was not possible to verify patient adherence with statin therapy despite evidence of prescription in the electronic medical record. However, patients in the antecedent statin group had better lipid profiles, suggestive of medication effect. Additionally, errors with data entry are unlikely to affect the primary endpoint, inpatient mortality. To increase the capacity for critical care interventions, multiple temporary intensive care units (ICU) were created in previously non-ICU patient care areas at our institution. Thus, assessment for need for ICU level-of-care or outcomes in ICU patients was not possible. We did, however, assess need for invasive mechanical ventilation as part of the key secondary endpoint, a therapy which was almost exclusively used in ICU settings. Further, patients who are receiving statins may reflect overall better outpatient care, and possibly a low-risk cohort. However, patients on statins were much older, and had a more severe burden of comorbidities in our study. Moreover, we examined proxy variables for socioeconomic status, including NYC borough of residence and medical insurance, and these were not significantly different between the two groups. Lastly, a small proportion of patients (2.5%) included in this analysis remained hospitalized at the end of study period, and so reporting on in-hospital outcomes in such patients remains incomplete at this time.

Conclusions {#S16}
===========

In this large analysis from a quaternary academic medical institution in an epicenter of the COVID-19 pandemic, we demonstrated that antecedent statin use was associated with significantly lower rates of in-hospital mortality within 30 days. These results indicate the important need for randomized controlled trials evaluating the benefits of statin therapy in patients affected by COVID-19.
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![Forest Plot for In-Hospital Mortality Within 30 Days. Forest plot demonstrating the odds ratio (OR) and 95% confidence interval (CI) for in-hospital mortality within 30 days with antecedent statin use (vs. no antecedent statin use) after multivariable logistic regression in the overall cohort. A number of other sociodemographic and baseline medication variables are also presented in this forest plot.](nihpp-rs56210v1-f0001){#F1}

![Forest Plot for In-hospital Mortality or Invasive Mechanical Ventilation Within 30 days. Forest plot demonstrating the odds ratio (OR) and 95% confidence interval (CI) for the composite endpoint of in-hospital mortality or invasive mechanical ventilation requirement within 30 days with antecedent statin use (vs. no antecedent statin use) after multivariable logistic regression in the overall cohort. A number of other sociodemographic and baseline medication variables are also presented in this forest plot.](nihpp-rs56210v1-f0002){#F2}

###### 

Baseline Characteristics in Unmatched and Propensity-Matched Cohorts of Patients Hospitalized with COVID-19

                                                        Unmatched               Matched                                                                        
  ---------------------------------------------------- ------------------------ ------------------------ --------- --------------------- --------------------- ---------
  **Demographics**                                                                                                                                             
  Age, years, median (IQR)                             70 (63 -- 79)            62 (49 -- 76)            \<0.001   69 (61 -- 77)         71 (60 -- 81)         0.18
  Body Mass Index (kg/m^2^)                            28.3 (24.7 -- 32.8)      27.9 (24.5 -- 32.6)      0.23      28.1 (24.7 -- 32.4)   27.1 (23.8 -- 32.0)   0.66
  Sex                                                                                                    0.06                                                  1.0
  Male                                                 519 (34.7%)              978 (65.3%)                        366 (56.5%)           366 (56.5%)           
  Female                                               432 (38.2%)              697 (61.7%)                        282 (43.5%)           282 (43.5%)           
  Race/Ethnicity                                                                                         0.12                                                  0.76
  Hispanic                                             489 (51.4%)              825 (49.2%)                        327 (50.5)            310 (47.8%)           
  Non-Hispanic White                                   88 (9.3%)                149 (8.9%)                         60 (9.3%)             68 (10.5%)            
  Non-Hispanic Black                                   126 (13.2%)              194 (11.6%)                        87 (13.4%)            87 (13.4%)            
  Others/Missing                                       248 (26.1%)              507 (30.3%)                        174 (26.9%)           183 (28.2%)           
  Location                                                                                               0.88                                                  0.50
  Manhattan                                            553 (58.1%)              936 (55.9%)                        371 (57.3%)           381 (58.8%)           
  Brooklyn                                             24 (2.5%)                46 (2.7%)                          16 (2.5%)             12 (1.9%)             
  Queens                                               29 (3.0%)                47 (2.8%)                          25 (3.9%)             16 (2.5%)             
  Bronx                                                294 (3.1%)               546 (3.3%)                         197 (30.4%)           209 (32.2%)           
  Staten Island                                        2 (0.2%)                 4 (0.2%)                           2 (0.3%)              1 (0.1%)              
  Outside NYC                                          49 (5.1%)                96 (5.7%)                          37 (5.7%)             29 (4.5%)             
  Insurance                                                                                              \<0.001                                               0.80
  Medicare/Medicaid                                    599 (63.0%)              896 (53.6%)                        396 (61.1%)           399 (61.6%)           
  Commercial                                           337 (35.4%)              710 (42.5%)                        241 (37.2%)           235 (36.2%)           
  Other/Uninsured                                      15 (1.6%)                65 (3.9%)                          11 (1.7%)             14 (2.1%)             
                                                                                                                                                               
  **Comorbidities**                                                                                                                                            
  Hypertension                                         704 (74.0%)              726 (43.3%)              \<0.001   434 (67.0%)           453 (69.9%)           0.28
  Diabetes                                             531 (55.8%)              437 (26.1%)              \<0.001   297 (45.8%)           309 (47.7%)           0.54
  Coronary Artery Disease                              214 (22.5%)              115 (6.9%)               \<0.001   96 (14.8%)            91 (14.0%)            0.75
  Heart Failure                                        162 (17.0%)              113 (6.7%)               \<0.001   91 (14.0%)            78 (12.0%)            0.32
  Chronic Lung Disease                                 196 (20.6%)              267 (15.9%)              \<0.01    124 (19.1%)           124 (19.1%)           1.0
  Chronic Kidney Disease                               209 (22.0%)              161 (9.6%)               \<0.001   116 (17.9%)           113 (17.4%)           0.88
  Stroke/TIA                                           132 (13.9%)              93 (5.6%)                \<0.001   68 (10.5%)            67 (10.3%)            1.0
  Atrial arrhythmias[\*](#TFN2){ref-type="table-fn"}   105 (11.0%)              118 (7.0%)               \<0.001   64 (9.9%)             61 (9.4%)             0.85
  Liver disease                                        31 (3.3%)                53 (3.2%)                0.98      22 (3.4%)             21 (3.2%)             1.0
                                                                                                                                                               
  **Home medications**                                                                                                                                         
  ACE inhibitors                                       187 (19.7%)              70 (4.2%)                \<0.001   76 (11.7%)            63 (9.7%)             0.28
  ARBs                                                 125 (13.1%)              62 (3.7%)                \<0.001   60 (9.3%)             52 (8.0%)             0.49
  P2Y12 inhibitors                                     113 (11.9%)              20 (1.1%)                \<0.001   35 (5.4%)             20 (3.1%)             0.05
  Oral anticoagulants                                  193 (20.3%)              206 (12.3%)              \<0.001   111 (17.1%)           118 (18.2%)           0.66
  Beta-blockers                                        419 (44.0%)              212 (12.7%)              \<0.001   194 (29.9%)           177 (27.3%)           0.32
                                                                                                                                                               
  **Inpatient statins**                                732 (77.0%)              144 (8.6%)               \<0.001   487 (75.1%)           86 (13.3%)            \<0.001
                                                                                                                                                               
  **Lipid profile (n = 850)**                                                                                                                                  
  Total Cholesterol                                    157.3 (127.7 -- 191.0)   164.9 (136.0 -- 201.9)   \<0.01                                                
  Low-Density Lipoprotein                              77.9 (60.0 -- 107.6)     88.0 (67.0 -- 117.0)     \<0.01                                                
  High-Density Lipoprotein                             43.0 (34.0 -- 54.4)      42.0 (32.4 -- 54.4)      0.25                                                  
  Triglycerides                                        136.0 (98.0 -- 187.8)    136.0 (93.7 -- 215.5)    0.22                                                  

Data are presented as N (%).

Any atrial fibrillation, atrial flutter, and supraventricular tachycardia. ACE = Angiotensin-converting enzyme, ARB = angiotensin receptor blocker, IQR = interquartile range, NYC = New York City, TIA = transient ischemic attack

###### 

Presenting Vital Signs and Laboratory Data in the Propensity-Matched Cohort of Patients Hospitalized with COVID-19

  -----------------------------------------------------------------------------------------------------
                                      Statins Use\              No Statins Use\           P-Value
                                      (n = 648)                 (n=648)                   
  ----------------------------------- ------------------------- ------------------------- -------------
  **Presenting vital signs**                                                              

  Temperature                         99.0 (98.2 -- 100.1)      98.8 (98.2 -- 100.0)      0.21

   Fever (temperature\>100.4 °F)      139 (21.4%)               129 (19.9%)               0.54

  Respiratory Rate                    18.0 (18.0 -- 20.0)       19.0 (18.0 -- 22.0)       0.19

   Tachypnea (RR\>21)                 143 (22.1%)               186 (28.7%)               **\<0.01**

   Oxygen saturation                  94.0 (91.0 -- 97.0)       94.0 (91.0 -- 96.0)       0.03

  Oxygen saturation \<92%             186 (28.7%)               204 (31.5%)               0.30

  Systolic Blood Pressure             123.0 (109.0 -- 139.0)    124.0 (110.0 -- 141.0)    0.38

  Diastolic Blood Pressure            72.0 (64.8 -- 81.0)       73.0 (65.0 -- 81.0)       0.08

   Hypotension (SBP\<90 mmHg)         25 (3.9%)                 15 (2.3%)                 0.15

  Heart rate                          96.0 (86.0 -- 109.3)      98.0 (86.0 -- 110.3)      0.47

   Tachycardia (HR\>100)              270 (41.7%)               287 (44.3%)               0.37

  **Presenting laboratory values**                                                        

  White blood cell count (10^3^/uL)   7.6 (5.5 -- 10.3)         8.1 (5.8 -- 11.6)         **\<0.01**

  Platelet count (10^3^/uL)           235.0 (159.0 -- 329.0)    224.0 (149.0 -- 314.0)    0.43

  Creatinine (mg/dL)                  1.8 (1.1 -- 3.3)          1.9 (1.1 -- 3.8)          0.19

  AST (U/L)                           81.0 (44.8 -- 126.3)      84.0 (45.5 -- 142.5)      0.32

  ALT (U/L)                           62.5 (33.3 -- 95.8)       60.5 (33.3 -- 107.3)      0.43

  Albumin (g/dL)                      3.6 (2.8 -- 4.4)          3.6 (2.7 -- 4.4)          0.93

  Lactate (mmol/L)                    2.8 (1.6 -- 4.2)          3.1 (1.8 -- 4.7)          0.35

  Hs-Troponin (ng/L)                  76.5 (34.3 -- 164.8)      88.0 (39.8 -- 162.3)      0.50

  D-dimer (ug/mL)                     2.1 (1.1 -- 3.7)          2.5 (1.3 -- 5.0)          0.37

  Ferritin (ng/mL)                    667.8 (335.1 -- 1248.5)   714.2 (368.2 -- 1299.0)   0.74

  ESR (mm/hour)                       67.5 (37.8 -- 97.3)       66.5 (36.3 -- 96.8)       0.84

  CRP (mg/L)                          100.0 (46.2 -- 168.5)     120.7 (61.2 -- 194.9)     **\<0.001**
  -----------------------------------------------------------------------------------------------------

Data presented as N (%) or median (IQR). ALT = alanine transaminase, AST = aspartate transaminase, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, F = Fahrenheit, HR = heart rate, IQR = interquartile range, IL-6 = interleukin 6, SBP = systolic blood pressure.

###### 

Clinical Outcomes in the Propensity-matched Cohort of Patients Hospitalized with COVID-19

  --------------------------------------------------------------------------------------
                                     Statins Use\         No Statins Use\      P-Value
                                     (n = 648)            (n = 648)            
  ---------------------------------- -------------------- -------------------- ---------
  Primary endpoint                   96 (14.8%)           172 (26.5%)          \<0.001

  Secondary endpoint                 179 (27.6%)          269 (41.5%)          \<0.001

  In-hospital mortality (anytime)    112 (17.2%)          201 (31.0%)          \<0.001

  Mechanical ventilation (anytime)   130 (20.1%)          158 (24.4%)          0.07

  Vasopressor use                    151 (23.3%)          200 (30.9%)          \<0.01

  CVVH                               37 (5.7%)            45 (6.9%)            0.42

  Length of hospital stay (days)     7.0 (4.0 -- 12.0)    7.0 (3.0 -- 14.0)    0.27

  Days on ventilator                 13.5 (3.8 -- 31.6)   12.8 (2.6 -- 34.7)   0.77
  --------------------------------------------------------------------------------------

Data presented as Kaplan Meier estimates N (%) or median (IQR).

###### 

Associations between Statin Use with Primary and Second Endpoints in Propensity-Matched Cohort and Multivariable-Adjusted Overall Cohorts of Patients Hospitalized with COVID-19

  Primary endpoint -- In-hospital mortality within 30 days                         
  ---------------------------------------------------------- ------ -------------- ---------
  PS-matched                                                 0.48   0.36 -- 0.63   \<0.001
  Multivariable (overall)                                    0.49   0.38 -- 0.63   \<0.001

CI = confidence interval and HR = hazard ratio, PS = propensity scoring
